Comment
0
Tweet
0
Print
RSS Feeds

Is Eli Lilly's Management Charting the Right Course?

Sunday - 3/24/2013, 9:00am  ET

In the following video, Motley Fool healthcare analyst David Williamson takes a look at Eli Lilly's  CEO, John Lechleiter, examining both how his background as a scientist makes him an a rarity in big pharma and highlighting his rise to the top of Eli Lilly. David then tells investors why Lechleiter's background is both a strength for the company -- and a potential weakness.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.